Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
26.44
+0.19 (0.72%)
Aug 10, 2026, 3:22 PM EDT - Market open
Dyne Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 676.11 | 893.37 | 435.45 | 121.63 | 172.15 | 200.83 |
Short-Term Investments | 222.36 | 217.19 | 206.82 | 1.47 | 83.87 | 175.75 |
Cash & Short-Term Investments | 898.48 | 1,111 | 642.27 | 123.1 | 256.01 | 376.57 |
Cash Growth | 31.37% | 72.91% | 421.75% | -51.92% | -32.02% | 9.05% |
Other Current Assets | 39.41 | 16.03 | 17.01 | 6.28 | 9.58 | 5.82 |
Total Current Assets | 937.89 | 1,127 | 659.28 | 129.38 | 265.59 | 382.39 |
Net Property, Plant & Equipment | 44.82 | 44.77 | 30.01 | 33.39 | 38.41 | 40.96 |
Other Long-Term Assets | 11.31 | 15.6 | 1.94 | 2.32 | 2.32 | 2.31 |
Total Assets | 994.01 | 1,187 | 691.23 | 165.08 | 306.33 | 425.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 12.15 | 8.08 | 6.56 | 22.94 | 5.26 | 4.03 |
Accrued Expenses | 46.36 | 37.55 | 30.85 | 23.44 | 18.22 | 20.8 |
Current Portion of Leases | 5.37 | 5 | 4.85 | 4.72 | 4.61 | 3.89 |
Other Current Liabilities | 14.15 | - | - | - | - | - |
Total Current Liabilities | 78.03 | 50.63 | 42.26 | 51.1 | 28.09 | 28.72 |
Long-Term Debt | 199.33 | 148.92 | - | - | - | - |
Long-Term Leases | 14.51 | 15.28 | 19.14 | 22.7 | 25.87 | 28.74 |
Total Long-Term Liabilities | 213.83 | 164.2 | 19.14 | 22.7 | 25.87 | 28.74 |
Total Liabilities | 291.86 | 214.83 | 61.4 | 73.79 | 53.96 | 57.47 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 2,398 | 2,368 | 1,580 | 723.8 | 649.5 | 596.93 |
Accumulated Other Comprehensive Income | -0.35 | 0.48 | 0.01 | - | -0.57 | -0.27 |
Retained Earnings | -1,696 | -1,396 | -949.93 | -632.51 | -396.57 | -228.47 |
Shareholders' Equity | 702.15 | 972.13 | 629.84 | 91.29 | 252.36 | 368.2 |
Total Liabilities & Equity | 994.01 | 1,187 | 691.23 | 165.08 | 306.33 | 425.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 219.2 | 169.2 | 23.99 | 27.42 | 30.48 | 32.64 |
Net Cash (Debt) | 679.28 | 941.36 | 618.28 | 95.69 | 225.53 | 343.94 |
Net Cash Growth | 20.69% | 52.25% | 546.16% | -57.57% | -34.43% | -0.40% |
Net Cash Per Share | 4.38 | 7.33 | 6.57 | 1.60 | 4.34 | 6.76 |
Book Value | 702.15 | 972.13 | 629.84 | 91.29 | 252.36 | 368.2 |
Book Value Per Share | 4.53 | 7.57 | 6.69 | 1.53 | 4.86 | 7.23 |
Tangible Book Value | 702.15 | 972.13 | 629.84 | 91.29 | 252.36 | 368.2 |
Tangible Book Value Per Share | 4.53 | 7.57 | 6.69 | 1.53 | 4.86 | 7.23 |